专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5525607A Xanthine compounds 失效
标题翻译：黄嘌呤化合物
公开(公告)号：US5525607A
公开(公告)日：1996-06-11
申请号：US63684
申请日：1993-05-20
申请人： Fumio Suzuki , Junichi Shimada , Akio Ishii , Tetsuji Ohno , Akira Karasawa , Kazuhiro Kubo , Hiromi Nonaka , Fumio Suzuki , Junichi Shimada , Akio Ishii , Tetsuji Ohno , Akira Karasawa , Kazuhiro Kubo , Hiromi Nonaka
发明人： Fumio Suzuki , Junichi Shimada , Akio Ishii , Tetsuji Ohno , Akira Karasawa , Kazuhiro Kubo , Hiromi Nonaka , Fumio Suzuki , Junichi Shimada , Akio Ishii , Tetsuji Ohno , Akira Karasawa , Kazuhiro Kubo , Hiromi Nonaka
IPC分类号： C07D473/06 , C07D473/08 , C07D473/20 , C07D473/22 , A61K31/52 , C07D473/00
CPC分类号： C07D473/06 , C07D473/08 , C07D473/20 , C07D473/22
摘要： Novel xanthine compounds represented by the following formula: ##STR1## wherein each of R.sup.1, R.sup.2 and R.sup.3 independently represents hydrogen or lower alkyl;each of X.sup.1 and X.sup.2 independently represents oxygen or sulfur; and Q represents: ##STR2## The compounds are useful as a diuretic, a renal-protecting agent and bronchodilator.
摘要翻译：由下式表示的新型黄嘌呤化合物：其中R 1，R 2和R 3各自独立地表示氢或低级烷基; X1和X2各自独立地表示氧或硫; Q表示：该化合物可用作利尿剂，肾保护剂和支气管扩张剂。

2. 发明申请

US20110105486A1 THIAZOLE DERIVATIVES 有权
标题翻译：噻唑衍生物
公开(公告)号：US20110105486A1
公开(公告)日：2011-05-05
申请号：US12960937
申请日：2010-12-06
申请人： Takao Nakajima , Masamori Sugawara , Shin-ichi Uchida , Tetsuji Ohno , Yuji Nomoto , Noriaki Uesaka , Yoshisuke Nakasato
发明人： Takao Nakajima , Masamori Sugawara , Shin-ichi Uchida , Tetsuji Ohno , Yuji Nomoto , Noriaki Uesaka , Yoshisuke Nakasato
IPC分类号： A61K31/541 , C07D277/38 , C07D417/14 , C07D401/14 , C07D213/89 , C07D413/14 , C07D279/12 , A61K31/426 , A61K31/4439 , A61K31/454 , A61K31/5377 , A61P25/28 , A61P25/00 , A61P3/10 , A61P25/12 , A61P25/24
CPC分类号： C07D417/06 , A61K31/427 , A61K31/438 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5383 , A61K31/541 , A61K31/542 , A61K31/551 , A61K31/553 , A61K31/695 , C07D417/04 , C07D417/14 , C07D491/048 , C07D491/10 , C07D498/04 , C07D513/04
摘要： Wherein n is an integer of from 0 to 3; R1A is a 5-membered aromatic heterocyclic group containing at least one oxygen atom; R2A is —COR8 (wherein R8 is aryl); R3A is hydrogen or lower alkyl; and R12 represents cycloalkyl, aryl, aralkyl, alicyclic heterocyclic group, aromatic heterocyclic group, alicyclic hetocyclic-alkyl, or aromatic heterocyclic-alkyl, and R1A, R2A, R3A and R12 are individually optionally substituted.
摘要翻译：其中n为0至3的整数; R1A是含有至少一个氧原子的5元芳族杂环基; R2A是-COR8（其中R8是芳基）; R3A是氢或低级烷基; R 12表示环烷基，芳基，芳烷基，脂环族杂环基，芳香族杂环基，脂环族环状烷基或芳香族杂环烷基，R1A，R2A，R3A，R12分别任意取代。

3. 发明申请

US20100256361A1 THIAZOLE DERIVATIVES 有权
标题翻译：噻唑衍生物
公开(公告)号：US20100256361A1
公开(公告)日：2010-10-07
申请号：US12766986
申请日：2010-04-26
申请人： Takao Nakajima , Masamori Sugawara , Shin-ichi Uchida , Tetsuji Ohno , Yuji Nomoto , Noriaki Uesaka , Yoshisuke Nakasato
发明人： Takao Nakajima , Masamori Sugawara , Shin-ichi Uchida , Tetsuji Ohno , Yuji Nomoto , Noriaki Uesaka , Yoshisuke Nakasato
IPC分类号： C07D417/14 , C07D413/14 , C07D498/04
CPC分类号： C07D417/06 , A61K31/427 , A61K31/438 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5383 , A61K31/541 , A61K31/542 , A61K31/551 , A61K31/553 , A61K31/695 , C07D417/04 , C07D417/14 , C07D491/048 , C07D491/10 , C07D498/04 , C07D513/04
摘要： (Wherein n is an integer of from 0 to 3; R1 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group; R2 is halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, —COR8, or the like; R3 and R4 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, —COR12, or the like)For example, provided are adenosine A2A receptor antagonists comprising, as the active ingredient, a thiazole derivative represented by a general formula (I), or a pharmaceutically acceptable salt thereof, and the like.
摘要翻译：（其中n为0〜3的整数; R 1为取代或未取代的环烷基，取代或未取代的芳基，取代或未取代的脂环族杂环基或取代或未取代的芳香族杂环基; R2为卤素，取代或未取代的低级烷基取代或未取代的芳基，取代或未取代的脂环族杂环基，取代或未取代的芳族杂环基，-COR 8等; R 3和R 4可以相同或不同，表示氢原子，取代或未取代的低级烷基，取代或未取代的芳烷基，-COR 12等）例如，提供的是腺苷A 2A受体拮抗剂，其包含作为活性成分的由通式（I）表示的噻唑衍生物或其药学上可接受的盐，以及类似。

4. 发明授权

US07122173B2 Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia 失效
公开(公告)号：US07122173B2
公开(公告)日：2006-10-17
申请号：US10473348
申请日：2002-03-29
申请人： Tsuyoshi Yamagata , Kaoru Atsuki , Tetsuji Ohno , Shiro Shirakura , Akira Karasawa , William C. de Groat , Naoki Yoshimura , Adrian Sculptoreanu
发明人： Tsuyoshi Yamagata , Kaoru Atsuki , Tetsuji Ohno , Shiro Shirakura , Akira Karasawa , William C. de Groat , Naoki Yoshimura , Adrian Sculptoreanu
IPC分类号： A61K10/00 , A61K49/00
CPC分类号： A61K31/55 , A61K31/38 , A61K31/44
摘要： The present invention provides an agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia, comprising, as an active ingredient, a compound having a slowly-inactivating A-type K+ channel opening activity or a pharmaceutically acceptable salt thereof, and a method for screening agents for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia, comprising measuring a slowly-inactivating A-type K+ channel opening activity as an index.

5. 发明授权

US6127541A Imidazoquinazoline derivatives 失效
标题翻译：咪唑喹唑啉衍生物
公开(公告)号：US6127541A
公开(公告)日：2000-10-03
申请号：US65061
申请日：1998-04-27
申请人： Yasuo Onoda , Yuji Nomoto , Tetsuji Ohno , Koji Yamada , Michio Ichimura
发明人： Yasuo Onoda , Yuji Nomoto , Tetsuji Ohno , Koji Yamada , Michio Ichimura
IPC分类号： C07D487/04 , C07D487/02
CPC分类号： C07D487/04
摘要： Imidazoquinoline derivatives of the formula ##STR1## (wherein X may be O or S) provide selective cyclic guanosine 3',5' monophosphate (cGMP)--specific phosphodiesterase (PDE) inhibitory activity. The compounds are useful for treating or ameliorating cardiovascular disease such as thrombosis, angina pectoris, hypertension, heart failure and arterial sclerosis, as well as asthma, impotence and the like.
摘要翻译： PCT No.PCT / JP97 / 03023 Sec。 371日期：1998年4月27日 102（e）日期1998年4月27日PCT 1997年8月29日PCT公布。出版物WO98 / 08848 日期：1998年3月5日式（其中X可以是O或S）的咪唑并喹啉衍生物提供选择性环状鸟苷3'，5'单磷酸（cGMP）特异性磷酸二酯酶（PDE）抑制活性。该化合物可用于治疗或改善心血管疾病如血栓形成，心绞痛，高血压，心力衰竭和动脉硬化，以及哮喘，阳ence等。

6. 发明授权

US5378701A Tricyclic compounds 失效
标题翻译：三环化合物
公开(公告)号：US5378701A
公开(公告)日：1995-01-03
申请号：US65916
申请日：1993-05-25
申请人： Etsuo Ohshima , Fumihiko Kanai , Hideyuki Sato , Hiroyuki Obase , Toshiaki Kumazawa , Shiho Takahara , Tetsuji Ohno , Tomoko Ishikawa , Koji Yamada
发明人： Etsuo Ohshima , Fumihiko Kanai , Hideyuki Sato , Hiroyuki Obase , Toshiaki Kumazawa , Shiho Takahara , Tetsuji Ohno , Tomoko Ishikawa , Koji Yamada
IPC分类号： C07D403/06 , C07D403/12 , C07D403/14 , C07D405/06 , C07D471/04 , C07D521/00 , A61K31/55 , C07D223/16 , C07D223/22
CPC分类号： C07D249/08 , C07D231/12 , C07D233/56 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/06 , C07D471/04
摘要： A tricyclic compound represented by the following formula (I): ##STR1## wherein R.sup.1 represents hydrogen, halogen or lower alkyl; A represents cyano, carboxyl, tetrazolyl, cyano-substituted phenyl, carboxyl-substituted phenyl or tetrazolyl-substituted phenyl; V represents --(CH.sub.2).sub.m -- wherein m is an integer of 0 to 2; W represents ##STR2## and Q.sup.1 --Q.sup.2 --Q.sup.3 --Q.sup.4 represents N.dbd.CH--CH.dbd.CH, CH.dbd.CH--CH.dbd.CH or CH.sub.2 --CH.sub.2 --CH.sub.2 --CH.sub.2, ##STR3## and Q represents N or CH; X.sup.1 --X.sup.2 --X.sup.3 represents CH.dbd.CH--CH.dbd.CH, S--CH.dbd.CH or CH.dbd.CH--S; Y represents CH.sub.2 CH.sub.2 ; and Z.sup.1 --Z.sup.2 represents N--(CH.sub.2).sub.n -- wherein n is an integer of 1 to 3 or a pharmaceutically acceptable salt thereof.
摘要翻译：由下式（I）表示的三环化合物：其中R 1表示氢，卤素或低级烷基; A代表氰基，羧基，四唑基，氰基取代的苯基，羧基取代的苯基或四唑基取代的苯基; V表示 - （CH 2）m - ，其中m是0至2的整数; W表示，Q1-Q2-Q3-Q4表示N = CH-CH = CH，CH = CH-CH = CH或CH2-CH2-CH2-CH2， N或CH; X1-X2-X3表示CH = CH-CH = CH，S-CH = CH或CH = CH-S; Y表示CH 2 CH 2; Z1-Z2表示N-（CH2）n-，其中n为1〜3的整数或其药学上可接受的盐。

7. 发明授权

US5173492A s-Triazolo(3,4-I)purine derivatives 失效
标题翻译：三唑并（3,4-I）嘌呤衍生物
公开(公告)号：US5173492A
公开(公告)日：1992-12-22
申请号：US752180
申请日：1991-08-23
申请人： Fumio Suzuki , Junichi Shimada , Kenji Ohmori , Haruhiko Manabe , Kazuihiro Kubo , Akira Karasawa , Tetsuji Ohno , Shizuo Shiozaki , Akio Ishii , Katsuichi Shuto
发明人： Fumio Suzuki , Junichi Shimada , Kenji Ohmori , Haruhiko Manabe , Kazuihiro Kubo , Akira Karasawa , Tetsuji Ohno , Shizuo Shiozaki , Akio Ishii , Katsuichi Shuto
IPC分类号： C07D471/14
CPC分类号： C07D471/14
摘要： There are disclosed s-triazolo[3,4-i]purine derivatives represented by formula: ##STR1## wherein Y-Z represents ##STR2## R.sub.4 represents hydrogen, alkyl, substituted or unsubstituted aromatic heterocyclic group or substituted or unsubstituted aryl; and X.sup.2 represents oxygen, sulfur or NH; each of R.sup.1 and R.sup.2 independently represents hydrogen, alkyl, cycloalkyl, aralkyl or substituted or unsubstituted aryl; R.sup.3 represents alkyl, cycloalkyl, aralkyl or substituted or unsubstituted aryl; X.sup.1 represents oxygen or sulfur; and represents a single bond or a double bond or pharmaceutically acceptable salts thereof.
摘要翻译：公开了由下式表示的三唑并[3,4-i]嘌呤衍生物：其中Y-Z表示R 4表示氢，烷基，取代或未取代的芳族杂环基或取代或未取代的芳基; X2表示氧，硫或NH; R 1和R 2各自独立地表示氢，烷基，环烷基，芳烷基或取代或未取代的芳基; R3表示烷基，环烷基，芳烷基或取代或未取代的芳基; X1表示氧或硫; 并且表示单键或双键或其药学上可接受的盐。

8. 发明授权

US07276532B2 Remedies for vesical hyperactivity 失效
标题翻译：用于膀胱活动过度的补救措施
公开(公告)号：US07276532B2
公开(公告)日：2007-10-02
申请号：US10472143
申请日：2002-03-29
申请人： Tsuyoshi Yamagata , Kaoru Atsuki , Tetsuji Ohno , Shiro Shirakura , Akira Karasawa
发明人： Tsuyoshi Yamagata , Kaoru Atsuki , Tetsuji Ohno , Shiro Shirakura , Akira Karasawa
IPC分类号： A61K31/38
CPC分类号： C07D495/04 , A61K31/55 , C07D337/12
摘要： The present invention provides a therapeutic agent for overactive bladder comprising, as an active ingredient, a tricyclic compound represented by formula (I): [wherein R1 represents a hydrogen atom, substituted or unsubstituted lower alkyl, and the like; X1—X2—X3 represents CR5═CR6—CR7═CR8, CR5═CR6—S, and the like; Y represents —CH2S—, —SOCH2—, and the like; and R2 represents a hydrogen atom, and the like] or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明提供一种活性过氧化物的治疗剂，其包含作为活性成分的由式（I）表示的三环化合物：其中R 1表示氢原子，取代或未取代的低级烷基，和类似; X 1 - 2 - - - - - - - - - - - - - - - - - - （3） CR 7 -CR 8，CR 5 -CR 6 -S等; Y表示-CH 2 -S-，-SOCH 2 - 等; 和R 2表示氢原子等]或其药学上可接受的盐。

9. 发明申请

US20070137359A1 Speed changing operation apparatus for vehicle 审中-公开
标题翻译：车辆变速操作装置
公开(公告)号：US20070137359A1
公开(公告)日：2007-06-21
申请号：US11529093
申请日：2006-09-28
申请人： Tetsuji Ohno , Masayuki Shinmura
发明人： Tetsuji Ohno , Masayuki Shinmura
IPC分类号： F16H59/04 , G05G1/10
CPC分类号： F16H59/0278 , Y10T74/2014 , Y10T74/20732
摘要： A lever assembly, which can be used as a speed changing apparatus for vehicle, can include an operating lever shaft. The operating lever shaft can be pivotally supported on a speed changing operation unit. An operating knob can be formed with a mounting bore for receiving a top end of the operating lever shaft and can also be adapted to be mounted on the top end of the operating lever shaft for carrying out a speed changing operation of a transmission of vehicle by pivoting the operating lever shaft. An engagement member can have a cylindrical configuration of substantially same inner circumferential configuration as an outer circumferential configuration of the operating lever shaft. The engagement member can be adapted to be received and secured within the mounting bore of the operating knob and can have nails that are elastically deformable by the operating lever shaft and engaged therewith when the operating lever shaft is inserted through the engagement member.
摘要翻译：可用作车辆变速装置的杠杆组件可包括操作杆轴。操作杆轴可以枢转地支撑在变速操作单元上。操作旋钮可以形成有用于接收操作杆轴的顶端的安装孔，并且还可以适于安装在操作杆轴的顶端上，用于通过以下方式执行车辆变速器的变速操作枢转操作杆轴。接合构件可以具有与操作杆轴的外周构造基本相同的内周构造的圆柱形构造。接合构件可以适于被接收并固定在操作旋钮的安装孔内，并且可以具有当操作杆轴插入通过接合构件时由操作杆轴可弹性变形并与其接合的钉子。

10. 发明申请

US20060276531A1 Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia 审中-公开
标题翻译：代理治疗膀胱刺激症状伴有良性前列腺增生
公开(公告)号：US20060276531A1
公开(公告)日：2006-12-07
申请号：US11503067
申请日：2006-08-14
申请人： Tsuyoshi Yamagata , Kaoru Atsuki , Tetsuji Ohno , Shiro Shirakura , Akira Karasawa , William de Groat , Naoki Yoshimura , Adrian Sculptoreanu
发明人： Tsuyoshi Yamagata , Kaoru Atsuki , Tetsuji Ohno , Shiro Shirakura , Akira Karasawa , William de Groat , Naoki Yoshimura , Adrian Sculptoreanu
IPC分类号： A61K31/381
CPC分类号： A61K31/55 , A61K31/38 , A61K31/44
摘要： The present invention provides an agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia, comprising, as an active ingredient, a compound having a slowly-inactivating A-type K+ channel opening activity or a pharmaceutically acceptable salt thereof, and a method for screening agents for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia, comprising measuring a slowly-inactivating A-type K+ channel opening activity as an index.
摘要翻译：本发明提供了一种用于治疗伴有良性前列腺增生的膀胱刺激症状的药剂，其包含作为活性成分的具有缓慢失活的A型K + / O通道开放活性的化合物或以及用于治疗伴有良性前列腺增生的膀胱刺激症状的筛选剂的方法，包括测量缓慢失活的A型K +通道开放活性作为指标。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式